Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOS: Cholinesterase Inhibitors in Alzheimer's Disease
NCT03454646Phase 4Not yet recruiting
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Jun 2024
- Primary completion
- Apr 2027
- Modality
- Reversible Covalent Inhibitors, Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of donepezil, galantamine, rivastigmine in Alzheimer's disease (AD), sponsored by Centre Hospitalier Universitaire de Bordeaux. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
donepezilgalantaminerivastigmine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03454646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03454646.